Sutro Biopharma (STRO) Change in Accured Expenses (2017 - 2025)

Sutro Biopharma has disclosed Change in Accured Expenses across 9 years of filings, most recently posting -$1.9 million for Q4 2025.

• Change in Accured Expenses for Q4 2025 came in at -$1.9 million, down 154.57% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.7 million (up 123.62% YoY), and the FY2025 annual result was $1.7 million, up 123.62% from the prior year.
• Change in Accured Expenses came in at -$1.9 million for Q4 2025 at Sutro Biopharma, down from $4.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.9 million in Q2 2023 to a low of -$6.8 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is -$505500.0 (2021), against an average of $12300.0.
• Across the five-year window, Change in Accured Expenses tumbled 2150.56% in 2022 and surged 1234.24% in 2023, its largest moves.
• Sutro Biopharma's Change in Accured Expenses stood at $2.9 million in 2021, then plunged by 86.48% to $396000.0 in 2022, then tumbled by 866.41% to -$3.0 million in 2023, then jumped by 75.49% to -$744000.0 in 2024, then tumbled by 154.57% to -$1.9 million in 2025.
• The last three Change in Accured Expenses figures came in at -$1.9 million (Q4 2025), $4.8 million (Q3 2025), and -$6.7 million (Q2 2025), per Business Quant data.